Humana Inc. Raises FY 2025 Adjusted EPS Guidance to $17.00, Reports 2Q25 GAAP EPS of $4.51 and Adjusted EPS of $6.27, Increases Revenue Guidance to At Least $128 Billion

Reuters
07/30
Humana Inc. Raises FY 2025 Adjusted EPS Guidance to $17.00, Reports 2Q25 GAAP EPS of $4.51 and Adjusted EPS of $6.27, Increases Revenue Guidance to At Least $128 Billion

Humana Inc. reported its financial results for the second quarter of 2025, showcasing significant performance metrics and updates. The company announced earnings per share $(EPS)$ of $4.51 on a GAAP basis, with an adjusted EPS of $6.27 for the quarter. Year-to-date EPS stood at $14.81 on a GAAP basis and $17.85 on an adjusted basis. The insurance segment benefit ratio was reported at 89.9%, aligning with the company's previous expectation of approximately 90%. Humana revised its full-year 2025 GAAP EPS guidance to approximately $13.77, down from the prior estimate of approximately $14.68. However, it raised its adjusted FY 2025 EPS guidance to approximately $17.00, from the previous guidance of approximately $16.25. In terms of revenue, Humana increased its full-year 2025 consolidated revenue guidance to at least $128 billion, up from the previous range of $126 billion to $128 billion. The company also affirmed its FY 2025 insurance segment benefit ratio guidance range of 90.1% to 90.5%. Humana highlighted the strategic focus on investing in improved outcomes, operational excellence, and enhancing customer and investor experiences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humana Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730069182) on July 30, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10